Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies Closes follow-on equity and convertible debt offerings for net proceeds of $599 million WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2019. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are very pleased with the company’s performance during the second quarter, which included record revenue and 46%
external link icon
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Complements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers Equivalent High Performance to Stainless Steel XCell™ ATF With Faster Implementation WALTHAM, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention system used by biologic drug manufacturers to intensify cell culture and improve the efficiency and productivity of upstream processes. This innovative new single-use format, which will be offered alongside the existing stainless steel line, significantly reduces implementation time and improves overall ease of use for Repligen’s biopharmaceutical manufacturing customers. The new XCell ATF format aligns with single-use and continuous processing workflows that biomanufacturers are increasingly
external link icon
Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
news icon
Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application.
news icon
Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application
corporate icon
Antibodies, rProteins
Therapeutic proteins treat a wide variety of clinical indications, including cancers, autoimmunity, inflammation, infectious disease and genetic disorders. Applications include the bioprocessing of monoclonal antibodies, antibody fragments, Fc and albumin fusions, blood factors, and protein-based vaccines.
external link icon
CORRECTION -- Repligen to Report Third Quarter 2015 Financial Results
WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial results on Thursday, November 5, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended September 30, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 63731917. In addition, a webcast will be accessible via the Investor Relations  section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 63731917. About Repligen
external link icon
Repligen to Present at 2015 Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
external link icon
Repligen to Present at the 2013 Stephens Fall Investment Conference
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 at 10:00 a.m. EST. The annual conference will take place November 12-13, 2013 at the New York Palace Hotel in New York. The Repligen presentation will not be webcast, however the slide presentation will be available on the Company's website at www.repligen.com ; see Events & Presentations under Investor Relations. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to
news icon
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing